MedKoo product information:

 Tamoxifen Citrate

SOLTAMOX™ solution, a nonsteroidal antiestrogen, is for oral administration. Each 5 mL solution contains 15.2 mg tamoxifen citrate, equivalent to 10 mg tamoxifen and the following inactive ingredients: ethanol, glycerol, propylene glycol, sorbitol solution, licorice flavor, aniseed flavor, purified water. Tamoxifen citrate has a molecular weight of 563.62, the pKa' is 8.85, the equilibrium solubility in water at 37°C is 0.5 mg/mL and in 0.02 N HCl at 37°C, it is 0.2 mg/mL.

tamoxifen citrate is the citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Mechanism of action

According to http://en.wikipedia.org/wiki/Tamoxifen, Tamoxifen competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects. It is a nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues. Tamoxifen causes cells to remain in the G0 and G1 phases of the cell cycle. Because it prevents (pre)cancerous cells from dividing but does not cause cell death, tamoxifen is cytostatic rather than cytocidal. Tamoxifen itself is a prodrug, having relatively little affinity for its target protein, the estrogen receptor. It is metabolized in the liver by the cytochrome P450 isoform CYP2D6 and CYP3A4 into active metabolites such as 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen (endoxifen) which have 30-100 times more affinity with the estrogen receptor than tamoxifen itself. These active metabolites compete with estrogen in the body for binding to the estrogen receptor. In breast tissue, 4-hydroxytamoxifen acts as an estrogen receptor antagonist so that transcription of estrogen-responsive genes is inhibited.

Tamoxifen binds to estrogen receptor (ER) which in turn interacts with DNA. The ER/tamoxifen complex recruits other proteins known as co-repressors to stop genes being switched on by estrogen. Some of these proteins include NCoR and SMRT. Tamoxifen function can be regulated by a number of different variables including growth factors.  Tamoxifen needs to block growth factor proteins such as ErbB2/HER2  because high levels of ErbB2 have been shown to occur in tamoxifen resistant cancers. Tamoxifen seems to require a protein PAX2 for its full anticancer effect.  In the presence of high PAX2 expression, the tamoxifen/estrogen receptor complex is able to suppress the expression of the pro-proliferative ERBB2 protein. In contrast, when AIB-1 expression is higher than PAX2, tamoxifen/estrogen receptor complex upregulates the expression of ERBB2 resulting in stimulation of breast cancer growth.

 1: Shaikh IA, Brown I, Wahle KW, Heys SD. Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids. Nutr Cancer. 2010 Apr;62(3):284-96. Review. PubMed PMID: 20358465.

2: Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009 Dec;70(12):1688-97. Review. PubMed PMID: 20141708.

3: Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy. 2010 Feb;30(2):217. Review. PubMed PMID: 20099995.

4: Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet. 2010 Jan;127(1):1-17. Epub 2009 Oct 8. Review. PubMed PMID: 19823875.

5: Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review. PubMed PMID: 19147868.

6: Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33. Epub 2008 Dec 3. Review. PubMed PMID: 19111841.

7: Petrakova K, Růzicková J, Fait V. [Therapeutic approaches for breast carcinoma]. Klin Onkol. 2008;21(4):131-40. Review. Czech. PubMed PMID: 19102218.

8: Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol. 2008;630:206-19. Review. PubMed PMID: 18637493.

9: Saynak M, Cosar-Alas R, Yurut-Caloglu V, Caloglu M, Kocak Z, Uzal C. Chemotherapy and cerebrovascular disease. J BUON. 2008 Jan-Mar;13(1):31-6. Review. PubMed PMID: 18404783.

10: Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31(2):127-41. Review. PubMed PMID: 18217789.

11: Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007 Dec;116(3):496-526. Epub 2007 Oct 9. Review. PubMed PMID: 18001838.

12: Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22. Review. PubMed PMID: 17993229.

13: Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63. Epub 2007 Feb 16. Review. PubMed PMID: 17309673.

14: Lupu R, Menendez JA. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology. 2006 Sep;147(9):4056-66. Epub 2006 Jun 29. Review. PubMed PMID: 16809439.

15: Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Semin Oncol. 2006 Apr;33(2 Suppl 7):S18-25. Review. PubMed PMID: 16730273.

16: Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol. 2006 Apr;33(2 Suppl 7):S13-7. Review. PubMed PMID: 16730272.

17: Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91. Review. PubMed PMID: 16550168.

18: Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast. 2006 Feb;15 Suppl 1:S30-40. Review. PubMed PMID: 16500238.

19: Fujita K. Cytochrome P450 and anticancer drugs. Curr Drug Metab. 2006 Jan;7(1):23-37. Review. PubMed PMID: 16454691.

20: Ganz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am J Med. 2005 Dec 19;118 Suppl 12B:136-41. PubMed PMID: 16414339.

21: Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2006 Jan;6(1):43-7. Review. PubMed PMID: 16375643.

22: Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett. 2006 Mar 8;234(1):73-80. Epub 2005 Nov 21. Review. PubMed PMID: 16303243.

23: van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs. 2005 Dec;23(6):513-22. Review. PubMed PMID: 16267627.

24: Navolanic PM, McCubrey JA. Pharmacological breast cancer therapy (review). Int J Oncol. 2005 Nov;27(5):1341-4. Review. PubMed PMID: 16211230.

25: Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005 Oct;6(10):780-9. Review. PubMed PMID: 16198984.

26: Johnston SR. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S145-57. Review. PubMed PMID: 16113091.

27: Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci. 2005 Aug;96(8):457-65. Review. PubMed PMID: 16108826.

28: Gradishar W. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer. Expert Rev Anticancer Ther. 2005 Jun;5(3):445-53. Review. PubMed PMID: 16001952.

29: Singh Ranger G. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors. J Clin Pharm Ther. 2005 Aug;30(4):313-7. Review. Erratum in: J Clin Pharm Ther. 2005 Oct;30(5):496. Sing Ranger, G [corrected to Singh Ranger, G]. PubMed PMID: 15985044.

30: Sharma R, Beith J, Hamilton A. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer. Breast. 2005 Jun;14(3):181-91. Epub 2005 Apr 26. Review. PubMed PMID: 15927827.

31: Zusman I. The soluble p51 protein in cancer diagnosis, prevention and therapy. In Vivo. 2005 May-Jun;19(3):591-8. Review. PubMed PMID: 15875781.

32: Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med Res Rev. 2005 Jul;25(4):453-72. Review. PubMed PMID: 15834856.

33: Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet. 2005;44(4):349-66. Review. PubMed PMID: 15828850.

34: Montano MM, Bianco NR, Deng H, Wittmann BM, Chaplin LC, Katzenellenbogen BS. Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen. Front Biosci. 2005 May 1;10:1440-61. Review. PubMed PMID: 15769636.

35: Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304. Review. PubMed PMID: 15762770.

36: Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev. 2005;37(1):41-213. Review. PubMed PMID: 15747500.

37: Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol. 2004;546:121-65. Review. PubMed PMID: 15584372.

38: Zusman I. Soluble tumor-associated antigens in cancer detection, prevention and therapy. Med Sci Monit. 2004 Dec;10(12):RA317-24. Review. PubMed PMID: 15567995.

39: Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab. 2004 Oct;5(5):415-42. Review. PubMed PMID: 15544435.

40: Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer. 2003 Oct 15;98(8):1578-86. Review. PubMed PMID: 14534872.

41: Fichtner I, Reszka R, Arndt D, Zeisig R. Animal experiments-an essential component for the development of liposomal anticancer agents. J Liposome Res. 2003 Feb;13(1):9-15. Review. PubMed PMID: 12725721.

42: Guetens G, De Boeck G, Wood M, Maes RA, Eggermont AA, Highley MS, van Oosterom AT, de Bruijn EA, Tjaden UR. Hyphenated techniques in anticancer drug monitoring. I. Capillary gas chromatography-mass spectrometry. J Chromatogr A. 2002 Nov 8;976(1-2):229-38. Review. PubMed PMID: 12462614.

43: Gianni L. The future of targeted therapy: combining novel agents. Oncology. 2002;63 Suppl 1:47-56. Review. PubMed PMID: 12422055.

44: Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology. 2001;61 Suppl 2:73-82. Review. PubMed PMID: 11694791.

45: Kim R, Osaki A, Toge T. A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review). Int J Oncol. 2001 Nov;19(5):1075-80. Review. PubMed PMID: 11605012.

46: Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001 Feb 1;19(3):881-94. Review. PubMed PMID: 11157042.

47: Zafonte BT, Hulit J, Amanatullah DF, Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP, Pestell RG. Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Front Biosci. 2000 Dec 1;5:D938-61. Review. PubMed PMID: 11102317.

48: Horikoshi N, Saotome T, Yoshida N, Aiba K. [Oral cancer chemotherapy in the clinic]. Gan To Kagaku Ryoho. 2000 Oct;27(11):1641-6. Review. Japanese. PubMed PMID: 11057313.

49: Kushner DJ, Baker A, Dunstall TG. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol. 1999 Feb;77(2):79-88. Review. PubMed PMID: 10535697.

50: Tominaga T. [Progress in breast cancer treatment over a quarter of a century]. Gan To Kagaku Ryoho. 1999 Jun;26 Suppl 1:99-109. Review. Japanese. PubMed PMID: 10410664.

51: Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998;52(1-3):79-98. Review. PubMed PMID: 10066074.

52: Lindner DJ, Kalvakolanu DV, Borden EC. Increasing effectiveness of interferon-alpha for malignancies. Semin Oncol. 1997 Jun;24(3 Suppl 9):S9-99-S9-104. Review. PubMed PMID: 9208879.

53: Wilking N, Isaksson E, von Schoultz E. Tamoxifen and secondary tumours. An update. Drug Saf. 1997 Feb;16(2):104-17. Review. PubMed PMID: 9067122.

54: Jordan VC. Tamoxifen treatment for breast cancer: concept to gold standard. Oncology (Williston Park). 1997 Feb;11(2 Suppl 1):7-13. Review. PubMed PMID: 9065921.

55: Vershinin AO, Kamnev AN. [Mechanisms of antitumor activity of carotenoids]. Vopr Med Khim. 1996 Oct-Dec;42(4):275-7. Review. Russian. PubMed PMID: 9254509.

56: Jovanović-Mićić D, Beleslin DB, Nikolić SS. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors]. Med Pregl. 1996;49(7-8):287-90. Review. Croatian. PubMed PMID: 8926945.

57: Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol. 1995 Dec;40(6):523-30. Review. PubMed PMID: 8703657; PubMed Central PMCID: PMC1365206.

58: Wiseman H. Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci. 1994 Mar;15(3):83-9. Review. PubMed PMID: 8184491.

59: Oh-ishi S. [Pharmacological mechanism of action and development of anti-steroid hormones]. Nippon Rinsho. 1994 Mar;52(3):679-84. Review. Japanese. PubMed PMID: 8164367.

60: Sonoo H, Kurebayashi J. [Recent development of endocrine treatment for breast cancer--new drugs and new treatment methods using tamoxifen]. Gan To Kagaku Ryoho. 1993 Dec;20(15):2289-99. Review. Japanese. PubMed PMID: 8259841.

61: Tsukagoshi S. [Recent trend on the development of new anticancer drugs]. Gan To Kagaku Ryoho. 1993 Mar;20(4):425-31. Review. Japanese. PubMed PMID: 8452379.

62: Boone CW, Steele VE, Kelloff GJ. Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res. 1992 Jun;267(2):251-5. Review. PubMed PMID: 1376427.

63: Silvestrini B. Lonidamine: an overview. Semin Oncol. 1991 Apr;18(2 Suppl 4):2-6. Review. PubMed PMID: 2031193.

64: Tjaden UR, de Bruijn EA. Chromatographic analysis of anticancer drugs. J Chromatogr. 1990 Oct 12;531:235-94. Review. PubMed PMID: 2258419.